Annual Income Statements for Sabra Healthcare REIT
This table shows Sabra Healthcare REIT's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.
Quarterly Income Statements for Sabra Healthcare REIT
This table shows Sabra Healthcare REIT's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.
| Metric |
|
Q3 2022 |
Q4 2022 |
Q1 2023 |
Q2 2023 |
Q3 2023 |
Q4 2023 |
Q1 2024 |
Q2 2024 |
Q3 2024 |
Q4 2024 |
Q1 2025 |
| Net Income / (Loss) Attributable to Common Shareholders |
|
-50 |
-85 |
-9.49 |
21 |
-15 |
17 |
26 |
24 |
30 |
47 |
40 |
| Consolidated Net Income / (Loss) |
|
-50 |
-85 |
-9.49 |
21 |
-15 |
17 |
26 |
24 |
30 |
47 |
40 |
| Net Income / (Loss) Continuing Operations |
|
-50 |
13 |
-9.49 |
22 |
-14 |
19 |
26 |
24 |
30 |
47 |
40 |
| Total Pre-Tax Income |
|
-45 |
3.49 |
-7.92 |
22 |
-14 |
18 |
27 |
24 |
29 |
47 |
40 |
| Total Revenue |
|
115 |
137 |
132 |
133 |
136 |
135 |
139 |
147 |
149 |
156 |
156 |
| Net Interest Income / (Expense) |
|
-27 |
-28 |
-29 |
-28 |
-28 |
-28 |
-28 |
-29 |
-29 |
-28 |
-27 |
| Total Interest Income |
|
0.00 |
- |
0.00 |
0.00 |
0.00 |
- |
0.00 |
0.00 |
0.00 |
- |
0.00 |
| Total Interest Expense |
|
27 |
28 |
29 |
28 |
28 |
28 |
28 |
29 |
29 |
28 |
27 |
| Long-Term Debt Interest Expense |
|
27 |
28 |
29 |
28 |
28 |
28 |
28 |
29 |
29 |
28 |
27 |
| Total Non-Interest Income |
|
142 |
165 |
160 |
161 |
164 |
163 |
168 |
176 |
178 |
184 |
184 |
| Service Charges on Deposit Accounts |
|
48 |
53 |
57 |
58 |
60 |
61 |
66 |
68 |
74 |
77 |
77 |
| Other Service Charges |
|
9.93 |
8.97 |
9.07 |
8.46 |
11 |
9.13 |
9.70 |
9.18 |
9.70 |
11 |
10 |
| Other Non-Interest Income |
|
84 |
103 |
96 |
94 |
93 |
93 |
92 |
99 |
95 |
96 |
96 |
| Provision for Credit Losses |
|
-0.22 |
0.15 |
-0.21 |
0.43 |
0.33 |
-0.36 |
-0.14 |
-0.16 |
-0.15 |
-0.13 |
-0.17 |
| Total Non-Interest Expense |
|
164 |
116 |
119 |
102 |
103 |
116 |
113 |
125 |
114 |
115 |
116 |
| Other Operating Expenses |
|
9.68 |
11 |
11 |
9.53 |
11 |
17 |
12 |
13 |
12 |
13 |
13 |
| Depreciation Expense |
|
47 |
50 |
53 |
44 |
43 |
43 |
43 |
42 |
43 |
42 |
43 |
| Impairment Charge |
|
61 |
21 |
7.06 |
0.00 |
0.00 |
7.27 |
3.14 |
15 |
0.00 |
- |
0.00 |
| Other Special Charges |
|
46 |
34 |
49 |
49 |
49 |
49 |
55 |
55 |
59 |
59 |
60 |
| Income Tax Expense |
|
0.58 |
0.12 |
0.73 |
0.33 |
0.46 |
0.49 |
0.45 |
0.44 |
-0.27 |
0.38 |
0.41 |
| Other Adjustments to Consolidated Net Income / (Loss) |
|
- |
- |
- |
-0.65 |
-0.65 |
- |
- |
0.08 |
0.21 |
- |
0.22 |
| Basic Earnings per Share |
|
($0.22) |
($0.37) |
($0.04) |
$0.09 |
($0.07) |
$0.08 |
$0.11 |
$0.10 |
$0.13 |
$0.20 |
$0.17 |
| Weighted Average Basic Shares Outstanding |
|
230.98M |
230.95M |
231.16M |
231.20M |
231.22M |
231.20M |
231.45M |
231.62M |
234.29M |
233.50M |
237.89M |
| Diluted Earnings per Share |
|
($0.22) |
($0.37) |
($0.04) |
$0.09 |
($0.07) |
$0.08 |
$0.11 |
$0.10 |
$0.13 |
$0.20 |
$0.17 |
| Weighted Average Diluted Shares Outstanding |
|
230.98M |
230.95M |
231.16M |
232.24M |
231.22M |
232.79M |
233.37M |
233.75M |
237.04M |
236.05M |
240.30M |
| Weighted Average Basic & Diluted Shares Outstanding |
|
230.98M |
231.16M |
231.20M |
231.22M |
231.22M |
231.48M |
231.50M |
234.26M |
236.59M |
237.91M |
237.94M |
| Cash Dividends to Common per Share |
|
$0.30 |
- |
$0.30 |
$0.30 |
$0.30 |
- |
$0.30 |
$0.30 |
$0.30 |
- |
$0.30 |
Annual Cash Flow Statements for Sabra Healthcare REIT
This table details how cash moves in and out of Sabra Healthcare REIT's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.
| Metric |
|
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
| Net Change in Cash & Equivalents |
|
-54 |
17 |
552 |
-527 |
-11 |
16 |
50 |
-62 |
-6.60 |
20 |
| Net Cash From Operating Activities |
|
121 |
176 |
136 |
361 |
372 |
355 |
356 |
316 |
301 |
311 |
| Net Cash From Continuing Operating Activities |
|
121 |
176 |
136 |
361 |
372 |
355 |
356 |
316 |
301 |
311 |
| Net Income / (Loss) Continuing Operations |
|
79 |
70 |
158 |
279 |
69 |
138 |
-113 |
-78 |
14 |
127 |
| Consolidated Net Income / (Loss) |
|
79 |
70 |
158 |
279 |
69 |
138 |
-113 |
-78 |
14 |
127 |
| Provision For Loan Losses |
|
13 |
5.54 |
17 |
39 |
1.24 |
1.86 |
3.94 |
0.14 |
0.19 |
-0.57 |
| Depreciation Expense |
|
63 |
68 |
114 |
191 |
182 |
177 |
179 |
188 |
183 |
170 |
| Amortization Expense |
|
5.28 |
5.68 |
7.78 |
10 |
10 |
8.42 |
8.37 |
11 |
12 |
10 |
| Non-Cash Adjustments to Reconcile Net Income |
|
-20 |
21 |
-73 |
-141 |
134 |
32 |
256 |
214 |
94 |
27 |
| Changes in Operating Assets and Liabilities, net |
|
-20 |
4.97 |
-88 |
-18 |
-24 |
-2.74 |
23 |
-20 |
-2.73 |
-23 |
| Net Cash From Investing Activities |
|
-489 |
142 |
-183 |
-258 |
263 |
-136 |
-336 |
-216 |
103 |
-109 |
| Net Cash From Continuing Investing Activities |
|
-489 |
142 |
-183 |
-258 |
263 |
-136 |
-336 |
-216 |
103 |
-109 |
| Purchase of Property, Leasehold Improvements and Equipment |
|
-3.69 |
-1.00 |
-6.95 |
-28 |
-25 |
-47 |
-43 |
-54 |
-85 |
-55 |
| Purchase of Investment Securities |
|
-524 |
-171 |
-440 |
-672 |
-64 |
-111 |
-397 |
-267 |
-106 |
-156 |
| Sale and/or Maturity of Investments |
|
33 |
314 |
183 |
434 |
347 |
22 |
104 |
101 |
289 |
102 |
| Other Investing Activities, net |
|
- |
- |
3.76 |
6.87 |
5.08 |
0.00 |
0.00 |
4.60 |
5.46 |
0.00 |
| Net Cash From Financing Activities |
|
314 |
-301 |
599 |
-629 |
-646 |
-202 |
30 |
-162 |
-410 |
-182 |
| Net Cash From Continuing Financing Activities |
|
314 |
-300 |
599 |
-629 |
-646 |
-202 |
30 |
-162 |
-410 |
-182 |
| Issuance of Debt |
|
289 |
69 |
434 |
0.00 |
639 |
0.00 |
792 |
204 |
-92 |
0.00 |
| Repayment of Debt |
|
-3.13 |
-244 |
-4.15 |
-159 |
-1,483 |
-3.07 |
-798 |
-81 |
-1.98 |
13 |
| Repurchase of Common Equity |
|
- |
- |
- |
-0.50 |
- |
80 |
- |
- |
- |
86 |
| Payment of Dividends |
|
-110 |
-119 |
-182 |
-325 |
-335 |
-278 |
-263 |
-277 |
-277 |
-280 |
| Other Financing Activities, Net |
|
-1.27 |
-5.94 |
351 |
-0.49 |
-16 |
-0.83 |
-9.32 |
-2.52 |
-36 |
-0.09 |
| Cash Interest Paid |
|
54 |
59 |
70 |
138 |
124 |
93 |
85 |
98 |
102 |
105 |
| Cash Income Taxes Paid |
|
0.66 |
0.85 |
0.71 |
1.80 |
3.91 |
2.44 |
1.84 |
1.66 |
1.67 |
1.39 |
Quarterly Cash Flow Statements for Sabra Healthcare REIT
This table details how cash moves in and out of Sabra Healthcare REIT's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.
| Metric |
|
Q3 2022 |
Q4 2022 |
Q1 2023 |
Q2 2023 |
Q3 2023 |
Q4 2023 |
Q1 2024 |
Q2 2024 |
Q3 2024 |
Q4 2024 |
Q1 2025 |
| Net Change in Cash & Equivalents |
|
-40 |
23 |
-15 |
-6.34 |
6.75 |
7.60 |
19 |
-24 |
27 |
-2.44 |
-37 |
| Net Cash From Operating Activities |
|
108 |
68 |
68 |
70 |
83 |
79 |
53 |
80 |
98 |
80 |
80 |
| Net Cash From Continuing Operating Activities |
|
108 |
68 |
68 |
70 |
83 |
79 |
53 |
80 |
98 |
80 |
80 |
| Net Income / (Loss) Continuing Operations |
|
-50 |
-85 |
-9.49 |
21 |
-15 |
17 |
26 |
24 |
30 |
47 |
40 |
| Consolidated Net Income / (Loss) |
|
-50 |
-85 |
-9.49 |
21 |
-15 |
17 |
26 |
24 |
30 |
47 |
40 |
| Provision For Loan Losses |
|
-0.22 |
0.15 |
-0.21 |
0.43 |
0.33 |
-0.36 |
-0.14 |
-0.16 |
-0.15 |
-0.13 |
-0.17 |
| Depreciation Expense |
|
47 |
50 |
53 |
44 |
43 |
43 |
43 |
42 |
43 |
42 |
43 |
| Amortization Expense |
|
2.80 |
2.79 |
3.01 |
3.08 |
3.09 |
3.09 |
3.07 |
3.07 |
2.61 |
1.73 |
1.73 |
| Non-Cash Adjustments to Reconcile Net Income |
|
80 |
116 |
31 |
7.17 |
45 |
11 |
8.33 |
14 |
8.79 |
-3.89 |
2.44 |
| Changes in Operating Assets and Liabilities, net |
|
28 |
-16 |
-8.62 |
-5.68 |
6.65 |
4.91 |
-28 |
-2.05 |
14 |
-6.75 |
-7.53 |
| Net Cash From Investing Activities |
|
-57 |
-31 |
113 |
-8.19 |
60 |
-62 |
-13 |
-57 |
-57 |
19 |
-16 |
| Net Cash From Continuing Investing Activities |
|
-57 |
-31 |
113 |
-8.19 |
60 |
-62 |
-13 |
-57 |
-57 |
19 |
-16 |
| Purchase of Property, Leasehold Improvements and Equipment |
|
-14 |
-21 |
-20 |
-18 |
-26 |
-21 |
-13 |
-12 |
-14 |
-16 |
-7.78 |
| Purchase of Investment Securities |
|
-65 |
-49 |
-53 |
-12 |
-0.90 |
-41 |
-1.30 |
-56 |
-80 |
-19 |
-11 |
| Sale and/or Maturity of Investments |
|
23 |
33 |
184 |
19 |
86 |
-0.20 |
0.39 |
6.96 |
36 |
59 |
1.13 |
| Other Investing Activities, net |
|
-1.33 |
5.43 |
1.43 |
2.70 |
0.70 |
0.63 |
0.62 |
4.11 |
0.60 |
-5.32 |
0.81 |
| Net Cash From Financing Activities |
|
-92 |
-14 |
-196 |
-68 |
-136 |
-9.36 |
-20 |
-46 |
-14 |
-101 |
-101 |
| Net Cash From Continuing Financing Activities |
|
-92 |
-14 |
-196 |
-68 |
-136 |
-9.36 |
-20 |
-46 |
-14 |
-101 |
-101 |
| Issuance of Debt |
|
-142 |
204 |
-106 |
20 |
-66 |
61 |
52 |
-15 |
22 |
-59 |
-24 |
| Issuance of Common Equity |
|
- |
- |
-1.85 |
-0.31 |
-0.04 |
-0.49 |
-2.61 |
39 |
35 |
- |
-5.39 |
| Repayment of Debt |
|
123 |
-148 |
-0.49 |
-0.49 |
-0.50 |
-0.50 |
-0.50 |
-0.51 |
-0.51 |
14 |
-0.52 |
| Payment of Dividends |
|
-69 |
-69 |
-69 |
-69 |
-69 |
-69 |
-69 |
-69 |
-70 |
-71 |
-71 |
| Other Financing Activities, Net |
|
-2.50 |
-0.01 |
-18 |
-18 |
-0.01 |
-0.01 |
-0.08 |
- |
- |
-0.01 |
-0.08 |
| Cash Interest Paid |
|
19 |
29 |
22 |
30 |
20 |
29 |
20 |
30 |
21 |
34 |
20 |
Annual Balance Sheets for Sabra Healthcare REIT
This table presents Sabra Healthcare REIT's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.
| Metric |
|
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
| Total Assets |
|
2,469 |
2,266 |
7,032 |
6,665 |
6,069 |
5,986 |
5,967 |
5,748 |
5,386 |
5,304 |
| Cash and Due from Banks |
|
7.43 |
26 |
519 |
50 |
39 |
59 |
112 |
49 |
41 |
60 |
| Restricted Cash |
|
9.81 |
9.00 |
69 |
9.43 |
10 |
6.45 |
3.89 |
4.62 |
5.43 |
5.87 |
| Trading Account Securities |
|
- |
- |
0.00 |
340 |
319 |
289 |
97 |
135 |
137 |
122 |
| Loans and Leases, Net of Allowance |
|
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Premises and Equipment, Net |
|
2,040 |
2,010 |
5,994 |
5,854 |
5,341 |
5,285 |
5,163 |
4,959 |
4,617 |
4,514 |
| Intangible Assets |
|
- |
26 |
167 |
131 |
102 |
83 |
54 |
40 |
31 |
27 |
| Other Assets |
|
300 |
195 |
283 |
281 |
258 |
263 |
537 |
559 |
554 |
574 |
| Total Liabilities & Shareholders' Equity |
|
2,469 |
2,266 |
7,032 |
6,665 |
6,069 |
5,986 |
5,967 |
5,748 |
5,386 |
5,304 |
| Total Liabilities |
|
1,415 |
1,250 |
3,595 |
3,411 |
2,581 |
2,576 |
2,587 |
2,691 |
2,584 |
2,562 |
| Short-Term Debt |
|
255 |
26 |
641 |
624 |
- |
- |
0.00 |
197 |
94 |
107 |
| Other Short-Term Payables |
|
35 |
40 |
103 |
95 |
- |
146 |
143 |
142 |
137 |
118 |
| Long-Term Debt |
|
1,125 |
1,185 |
2,753 |
2,608 |
2,402 |
2,372 |
2,394 |
2,310 |
2,320 |
2,311 |
| Other Long-Term Liabilities |
|
- |
0.00 |
98 |
84 |
179 |
58 |
50 |
42 |
33 |
27 |
| Commitments & Contingencies |
|
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Total Equity & Noncontrolling Interests |
|
1,054 |
1,016 |
3,437 |
3,255 |
3,488 |
3,409 |
3,380 |
3,056 |
2,803 |
2,741 |
| Total Preferred & Common Equity |
|
1,054 |
1,016 |
3,433 |
3,250 |
3,488 |
3,409 |
3,380 |
3,056 |
2,803 |
2,741 |
| Preferred Stock |
|
0.06 |
0.06 |
0.06 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Total Common Equity |
|
1,054 |
1,016 |
3,433 |
3,250 |
3,488 |
3,409 |
3,380 |
3,056 |
2,803 |
2,741 |
| Common Stock |
|
1,203 |
1,210 |
3,639 |
3,510 |
4,074 |
4,165 |
4,485 |
4,489 |
4,497 |
4,595 |
| Accumulated Other Comprehensive Income / (Loss) |
|
-7.33 |
-1.80 |
11 |
12 |
-12 |
-40 |
-10 |
19 |
24 |
21 |
| Other Equity Adjustments |
|
-142 |
-192 |
-217 |
-272 |
-573 |
-716 |
-1,095 |
-1,452 |
-1,718 |
-1,875 |
Quarterly Balance Sheets for Sabra Healthcare REIT
This table presents Sabra Healthcare REIT's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.
| Metric |
|
Q3 2022 |
Q1 2023 |
Q2 2023 |
Q3 2023 |
Q1 2024 |
Q2 2024 |
Q3 2024 |
Q1 2025 |
| Total Assets |
|
5,845 |
5,556 |
5,524 |
5,381 |
5,374 |
5,351 |
5,366 |
5,233 |
| Cash and Due from Banks |
|
26 |
34 |
27 |
33 |
60 |
36 |
63 |
23 |
| Restricted Cash |
|
4.86 |
5.15 |
5.15 |
5.60 |
6.00 |
5.91 |
5.97 |
6.24 |
| Trading Account Securities |
|
208 |
139 |
140 |
136 |
132 |
130 |
131 |
121 |
| Loans and Leases, Net of Allowance |
|
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Premises and Equipment, Net |
|
5,019 |
4,797 |
4,752 |
4,603 |
4,577 |
4,566 |
4,574 |
4,488 |
| Intangible Assets |
|
48 |
39 |
36 |
33 |
28 |
28 |
29 |
25 |
| Other Assets |
|
539 |
542 |
564 |
570 |
571 |
585 |
563 |
571 |
| Total Liabilities & Shareholders' Equity |
|
5,845 |
5,556 |
5,524 |
5,381 |
5,374 |
5,351 |
5,366 |
5,233 |
| Total Liabilities |
|
2,636 |
2,580 |
2,581 |
2,512 |
2,607 |
2,589 |
2,621 |
2,531 |
| Short-Term Debt |
|
139 |
80 |
101 |
33 |
146 |
130 |
153 |
83 |
| Other Short-Term Payables |
|
145 |
143 |
122 |
128 |
113 |
113 |
123 |
112 |
| Long-Term Debt |
|
2,308 |
2,317 |
2,320 |
2,317 |
2,317 |
2,316 |
2,318 |
2,311 |
| Other Long-Term Liabilities |
|
44 |
40 |
39 |
34 |
31 |
30 |
28 |
25 |
| Commitments & Contingencies |
|
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Total Equity & Noncontrolling Interests |
|
3,209 |
2,976 |
2,944 |
2,869 |
2,767 |
2,762 |
2,745 |
2,702 |
| Total Preferred & Common Equity |
|
3,209 |
2,976 |
2,944 |
2,869 |
2,767 |
2,762 |
2,745 |
2,702 |
| Preferred Stock |
|
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Total Common Equity |
|
3,209 |
2,976 |
2,944 |
2,869 |
2,767 |
2,762 |
2,745 |
2,702 |
| Common Stock |
|
4,487 |
4,490 |
4,491 |
4,494 |
4,498 |
4,539 |
4,577 |
4,594 |
| Accumulated Other Comprehensive Income / (Loss) |
|
19 |
17 |
32 |
40 |
31 |
31 |
17 |
15 |
| Other Equity Adjustments |
|
-1,297 |
-1,531 |
-1,580 |
-1,665 |
-1,762 |
-1,808 |
-1,849 |
-1,907 |
Annual Metrics And Ratios for Sabra Healthcare REIT
This table displays calculated financial ratios and metrics derived from Sabra Healthcare REIT's official financial filings.
| Metric |
|
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
| Growth Metrics |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Revenue Growth |
|
44.69% |
9.78% |
20.91% |
95.41% |
3.60% |
-9.43% |
-25.54% |
18.59% |
3.43% |
10.29% |
| EBITDA Growth |
|
57.51% |
-2.10% |
57.28% |
57.83% |
-25.59% |
20.76% |
-80.37% |
265.38% |
24.97% |
5.33% |
| EBIT Growth |
|
70.82% |
-11.12% |
50.21% |
48.95% |
-51.73% |
80.88% |
-188.92% |
127.22% |
182.90% |
32.26% |
| NOPAT Growth |
|
69.23% |
-11.56% |
51.77% |
48.00% |
-53.32% |
110.58% |
-56.90% |
-52.47% |
167.89% |
47.00% |
| Net Income Growth |
|
69.23% |
-11.56% |
125.60% |
76.23% |
-75.27% |
100.55% |
-181.82% |
31.48% |
117.73% |
821.14% |
| EPS Growth |
|
42.31% |
-17.12% |
52.17% |
7.86% |
-75.50% |
81.08% |
-177.61% |
34.62% |
117.65% |
800.00% |
| Operating Cash Flow Growth |
|
41.91% |
45.27% |
-22.82% |
165.55% |
3.30% |
-4.73% |
0.43% |
-11.41% |
-4.80% |
3.32% |
| Free Cash Flow Firm Growth |
|
61.53% |
186.43% |
-1,720.76% |
111.17% |
33.25% |
-60.59% |
-71.81% |
226.05% |
77.91% |
-57.66% |
| Invested Capital Growth |
|
19.70% |
-8.52% |
206.87% |
-5.05% |
-9.19% |
-1.85% |
-0.13% |
-3.65% |
-6.23% |
-1.11% |
| Revenue Q/Q Growth |
|
-5.22% |
-3.00% |
4.06% |
-11.30% |
41.16% |
5.66% |
-26.99% |
19.48% |
-0.30% |
3.63% |
| EBITDA Q/Q Growth |
|
3.67% |
-3.20% |
41.93% |
-36.16% |
229.83% |
41.24% |
-73.67% |
38.10% |
45.30% |
8.01% |
| EBIT Q/Q Growth |
|
1.88% |
-5.74% |
44.86% |
-55.34% |
169.66% |
214.64% |
-319.46% |
230.46% |
4,650.14% |
24.28% |
| NOPAT Q/Q Growth |
|
0.93% |
-2.65% |
37.37% |
-61.17% |
324.67% |
256.24% |
-72.43% |
2,248.50% |
73.49% |
21.53% |
| Net Income Q/Q Growth |
|
3.72% |
-2.65% |
104.19% |
-30.65% |
597.57% |
233.92% |
-336.92% |
-356.23% |
115.57% |
30.40% |
| EPS Q/Q Growth |
|
-7.50% |
-3.16% |
47.37% |
-36.82% |
1,133.33% |
-6.94% |
-136.36% |
-277.78% |
115.38% |
28.57% |
| Operating Cash Flow Q/Q Growth |
|
29.92% |
0.07% |
42.38% |
-1.36% |
5.06% |
-1.69% |
2.45% |
-8.77% |
3.85% |
0.40% |
| Free Cash Flow Firm Q/Q Growth |
|
12.55% |
3.13% |
-9.77% |
957.74% |
-22.80% |
86.27% |
4,915.69% |
-35.14% |
-11.26% |
72.12% |
| Invested Capital Q/Q Growth |
|
1.47% |
1.14% |
7.13% |
-3.70% |
0.09% |
-0.10% |
-4.26% |
-1.64% |
-0.03% |
-1.08% |
| Profitability Metrics |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| EBITDA Margin |
|
61.62% |
54.96% |
71.49% |
57.74% |
41.47% |
55.30% |
14.58% |
44.91% |
54.26% |
51.82% |
| EBIT Margin |
|
33.25% |
26.93% |
33.45% |
25.50% |
11.88% |
23.72% |
-28.33% |
6.50% |
17.79% |
21.33% |
| Profit (Net Income) Margin |
|
32.94% |
26.54% |
49.52% |
44.66% |
10.66% |
23.60% |
-25.94% |
-14.99% |
2.57% |
21.45% |
| Tax Burden Percent |
|
99.07% |
98.53% |
99.60% |
97.06% |
87.13% |
88.89% |
-140.39% |
-358.14% |
73.74% |
98.91% |
| Interest Burden Percent |
|
100.00% |
100.04% |
148.63% |
180.45% |
102.99% |
111.93% |
-65.21% |
64.34% |
19.58% |
101.66% |
| Effective Tax Rate |
|
0.93% |
1.47% |
0.41% |
1.05% |
4.29% |
0.46% |
2.29% |
5.73% |
10.73% |
0.78% |
| Return on Invested Capital (ROIC) |
|
3.55% |
3.01% |
2.35% |
2.37% |
1.19% |
2.66% |
1.16% |
0.56% |
1.58% |
2.41% |
| ROIC Less NNEP Spread (ROIC-NNEP) |
|
3.55% |
3.01% |
4.60% |
6.03% |
1.03% |
1.96% |
-6.40% |
-3.90% |
-1.32% |
2.48% |
| Return on Net Nonoperating Assets (RNNOA) |
|
4.40% |
3.77% |
4.76% |
5.97% |
0.86% |
1.36% |
-4.49% |
-2.97% |
-1.11% |
2.16% |
| Return on Equity (ROE) |
|
7.96% |
6.78% |
7.11% |
8.34% |
2.05% |
4.01% |
-3.34% |
-2.41% |
0.47% |
4.57% |
| Cash Return on Invested Capital (CROIC) |
|
-14.38% |
11.91% |
-99.34% |
7.55% |
10.82% |
4.52% |
1.29% |
4.28% |
8.01% |
3.52% |
| Operating Return on Assets (OROA) |
|
3.53% |
3.01% |
2.30% |
2.33% |
1.21% |
2.31% |
-2.07% |
0.58% |
1.71% |
2.36% |
| Return on Assets (ROA) |
|
3.50% |
2.97% |
3.41% |
4.08% |
1.08% |
2.30% |
-1.90% |
-1.33% |
0.25% |
2.37% |
| Return on Common Equity (ROCE) |
|
7.95% |
6.78% |
7.11% |
8.33% |
2.05% |
4.01% |
-3.34% |
-2.41% |
0.47% |
4.57% |
| Return on Equity Simple (ROE_SIMPLE) |
|
7.53% |
6.91% |
4.61% |
8.59% |
1.98% |
4.06% |
-3.35% |
-2.54% |
0.49% |
4.62% |
| Net Operating Profit after Tax (NOPAT) |
|
79 |
70 |
107 |
158 |
74 |
155 |
67 |
32 |
85 |
125 |
| NOPAT Margin |
|
32.94% |
26.54% |
33.31% |
25.23% |
11.37% |
26.43% |
15.30% |
6.13% |
15.88% |
21.17% |
| Net Nonoperating Expense Percent (NNEP) |
|
0.00% |
0.00% |
-2.25% |
-3.66% |
0.16% |
0.70% |
7.55% |
4.46% |
2.90% |
-0.07% |
| SG&A Expenses to Revenue |
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| Operating Expenses to Revenue |
|
66.75% |
73.07% |
66.55% |
74.50% |
88.12% |
76.28% |
127.43% |
93.47% |
82.18% |
78.76% |
| Earnings before Interest and Taxes (EBIT) |
|
80 |
71 |
107 |
159 |
77 |
139 |
-124 |
34 |
95 |
126 |
| Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) |
|
148 |
145 |
229 |
361 |
269 |
324 |
64 |
233 |
291 |
306 |
| Valuation Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Price to Book Value (P/BV) |
|
0.59 |
0.81 |
0.54 |
0.55 |
0.79 |
0.77 |
0.72 |
0.78 |
1.07 |
1.47 |
| Price to Tangible Book Value (P/TBV) |
|
0.59 |
0.83 |
0.57 |
0.58 |
0.81 |
0.79 |
0.73 |
0.79 |
1.08 |
1.48 |
| Price to Revenue (P/Rev) |
|
2.59 |
3.10 |
5.84 |
2.88 |
4.26 |
4.46 |
5.54 |
4.58 |
5.60 |
6.81 |
| Price to Earnings (P/E) |
|
9.01 |
13.65 |
12.61 |
6.68 |
39.98 |
18.88 |
0.00 |
0.00 |
217.85 |
31.76 |
| Dividend Yield |
|
16.72% |
13.30% |
12.21% |
17.84% |
12.64% |
10.69% |
11.33% |
11.69% |
9.26% |
7.06% |
| Earnings Yield |
|
11.10% |
7.33% |
7.93% |
14.97% |
2.50% |
5.30% |
0.00% |
0.00% |
0.46% |
3.15% |
| Enterprise Value to Invested Capital (EV/IC) |
|
0.82 |
0.90 |
0.69 |
0.77 |
0.87 |
0.85 |
0.81 |
0.87 |
1.03 |
1.24 |
| Enterprise Value to Revenue (EV/Rev) |
|
8.24 |
7.54 |
14.63 |
7.96 |
7.89 |
8.39 |
10.76 |
9.32 |
10.02 |
10.79 |
| Enterprise Value to EBITDA (EV/EBITDA) |
|
13.37 |
13.73 |
20.47 |
13.79 |
19.03 |
15.17 |
73.84 |
20.74 |
18.46 |
20.83 |
| Enterprise Value to EBIT (EV/EBIT) |
|
24.78 |
28.02 |
43.74 |
31.22 |
66.46 |
35.36 |
0.00 |
143.23 |
56.30 |
50.59 |
| Enterprise Value to NOPAT (EV/NOPAT) |
|
25.02 |
28.42 |
43.92 |
31.55 |
69.44 |
31.74 |
70.35 |
151.93 |
63.07 |
50.99 |
| Enterprise Value to Operating Cash Flow (EV/OCF) |
|
16.40 |
11.34 |
34.46 |
13.80 |
13.72 |
13.87 |
13.19 |
15.28 |
17.85 |
20.53 |
| Enterprise Value to Free Cash Flow (EV/FCFF) |
|
0.00 |
7.19 |
0.00 |
9.90 |
7.63 |
18.64 |
63.17 |
19.89 |
12.43 |
34.89 |
| Leverage & Solvency |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Debt to Equity |
|
1.31 |
1.19 |
0.99 |
0.99 |
0.69 |
0.70 |
0.71 |
0.82 |
0.86 |
0.88 |
| Long-Term Debt to Equity |
|
1.07 |
1.17 |
0.80 |
0.80 |
0.69 |
0.70 |
0.71 |
0.76 |
0.83 |
0.84 |
| Financial Leverage |
|
1.24 |
1.25 |
1.03 |
0.99 |
0.84 |
0.69 |
0.70 |
0.76 |
0.84 |
0.87 |
| Leverage Ratio |
|
2.27 |
2.29 |
2.09 |
2.05 |
1.89 |
1.75 |
1.76 |
1.82 |
1.90 |
1.93 |
| Compound Leverage Factor |
|
2.27 |
2.29 |
3.10 |
3.69 |
1.95 |
1.96 |
-1.15 |
1.17 |
0.37 |
1.96 |
| Debt to Total Capital |
|
56.70% |
54.38% |
49.69% |
49.82% |
40.78% |
41.03% |
41.47% |
45.06% |
46.28% |
46.86% |
| Short-Term Debt to Total Capital |
|
10.48% |
1.17% |
9.38% |
9.62% |
0.00% |
0.00% |
0.00% |
3.54% |
1.81% |
2.07% |
| Long-Term Debt to Total Capital |
|
46.22% |
53.21% |
40.30% |
40.21% |
40.78% |
41.03% |
41.47% |
41.52% |
44.47% |
44.80% |
| Preferred Equity to Total Capital |
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| Noncontrolling Interests to Total Capital |
|
0.00% |
0.00% |
0.07% |
0.07% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| Common Equity to Total Capital |
|
43.30% |
45.61% |
50.25% |
50.11% |
59.22% |
58.97% |
58.53% |
54.94% |
53.72% |
53.14% |
| Debt to EBITDA |
|
9.29 |
8.33 |
14.85 |
8.96 |
8.94 |
7.32 |
37.62 |
10.78 |
8.31 |
7.90 |
| Net Debt to EBITDA |
|
9.18 |
8.09 |
12.28 |
8.79 |
8.76 |
7.11 |
35.80 |
10.55 |
8.15 |
7.68 |
| Long-Term Debt to EBITDA |
|
7.57 |
8.15 |
12.04 |
7.23 |
8.94 |
7.32 |
37.62 |
9.93 |
7.98 |
7.55 |
| Debt to NOPAT |
|
17.38 |
17.24 |
31.86 |
20.50 |
32.63 |
15.30 |
35.84 |
78.95 |
28.38 |
19.34 |
| Net Debt to NOPAT |
|
17.16 |
16.75 |
26.35 |
20.12 |
31.96 |
14.88 |
34.11 |
77.26 |
27.83 |
18.81 |
| Long-Term Debt to NOPAT |
|
14.17 |
16.87 |
25.84 |
16.54 |
32.63 |
15.30 |
35.84 |
72.75 |
27.27 |
18.48 |
| Noncontrolling Interest Sharing Ratio |
|
0.01% |
0.01% |
0.10% |
0.13% |
0.06% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| Liquidity Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Cash Flow Metrics |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Free Cash Flow to Firm (FCFF) |
|
-321 |
278 |
-4,499 |
503 |
670 |
264 |
74 |
243 |
432 |
183 |
| Operating Cash Flow to CapEx |
|
3,282.76% |
17,540.18% |
1,952.67% |
1,301.90% |
1,463.50% |
749.36% |
835.60% |
579.61% |
354.22% |
567.59% |
| Free Cash Flow to Firm to Interest Expense |
|
0.00 |
0.00 |
-50.87 |
0.00 |
0.00 |
0.00 |
0.75 |
2.30 |
3.82 |
1.59 |
| Operating Cash Flow to Interest Expense |
|
0.00 |
0.00 |
1.54 |
0.00 |
0.00 |
0.00 |
3.61 |
2.99 |
2.66 |
2.69 |
| Operating Cash Flow Less CapEx to Interest Expense |
|
0.00 |
0.00 |
1.46 |
0.00 |
0.00 |
0.00 |
3.18 |
2.48 |
1.91 |
2.22 |
| Efficiency Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Asset Turnover |
|
0.11 |
0.11 |
0.07 |
0.09 |
0.10 |
0.10 |
0.07 |
0.09 |
0.10 |
0.11 |
| Fixed Asset Turnover |
|
0.13 |
0.13 |
0.08 |
0.11 |
0.12 |
0.11 |
0.08 |
0.10 |
0.11 |
0.13 |
| Capital & Investment Metrics |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Invested Capital |
|
2,434 |
2,226 |
6,832 |
6,487 |
5,891 |
5,782 |
5,774 |
5,563 |
5,217 |
5,159 |
| Invested Capital Turnover |
|
0.11 |
0.11 |
0.07 |
0.09 |
0.10 |
0.10 |
0.08 |
0.09 |
0.10 |
0.11 |
| Increase / (Decrease) in Invested Capital |
|
401 |
-207 |
4,605 |
-345 |
-596 |
-109 |
-7.60 |
-211 |
-347 |
-58 |
| Enterprise Value (EV) |
|
1,986 |
1,995 |
4,680 |
4,976 |
5,112 |
4,920 |
4,700 |
4,824 |
5,364 |
6,375 |
| Market Capitalization |
|
623 |
819 |
1,868 |
1,799 |
2,759 |
2,613 |
2,421 |
2,371 |
2,997 |
4,024 |
| Book Value per Share |
|
$16.18 |
$15.56 |
$19.26 |
$18.23 |
$18.01 |
$16.48 |
$14.78 |
$13.23 |
$12.12 |
$11.59 |
| Tangible Book Value per Share |
|
$16.18 |
$15.16 |
$18.32 |
$17.50 |
$17.49 |
$16.08 |
$14.54 |
$13.06 |
$11.99 |
$11.47 |
| Total Capital |
|
2,434 |
2,226 |
6,832 |
6,487 |
5,891 |
5,782 |
5,774 |
5,563 |
5,217 |
5,159 |
| Total Debt |
|
1,380 |
1,211 |
3,394 |
3,232 |
2,402 |
2,372 |
2,394 |
2,507 |
2,414 |
2,418 |
| Total Long-Term Debt |
|
1,125 |
1,185 |
2,753 |
2,608 |
2,402 |
2,372 |
2,394 |
2,310 |
2,320 |
2,311 |
| Net Debt |
|
1,363 |
1,176 |
2,807 |
3,172 |
2,353 |
2,307 |
2,279 |
2,453 |
2,367 |
2,351 |
| Capital Expenditures (CapEx) |
|
3.69 |
1.00 |
6.95 |
28 |
25 |
47 |
43 |
54 |
85 |
55 |
| Net Nonoperating Expense (NNE) |
|
0.00 |
0.00 |
-52 |
-121 |
4.59 |
17 |
180 |
109 |
71 |
-1.68 |
| Net Nonoperating Obligations (NNO) |
|
1,380 |
1,211 |
3,394 |
3,232 |
2,402 |
2,372 |
2,394 |
2,507 |
2,414 |
2,418 |
| Total Depreciation and Amortization (D&A) |
|
68 |
74 |
122 |
202 |
192 |
185 |
187 |
199 |
195 |
180 |
| Earnings Adjustments |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Adjusted Basic Earnings per Share |
|
$1.11 |
$0.92 |
$1.40 |
$1.51 |
$0.37 |
$0.00 |
($0.52) |
($0.34) |
$0.06 |
$0.54 |
| Adjusted Weighted Average Basic Shares Outstanding |
|
62.24M |
65.28M |
105.62M |
178.31M |
187.17M |
0.00 |
219.07M |
230.95M |
231.20M |
233.50M |
| Adjusted Diluted Earnings per Share |
|
$1.11 |
$0.92 |
$1.40 |
$1.51 |
$0.37 |
$0.00 |
($0.52) |
($0.34) |
$0.06 |
$0.54 |
| Adjusted Weighted Average Diluted Shares Outstanding |
|
62.46M |
65.52M |
105.84M |
178.72M |
188.13M |
0.00 |
219.07M |
230.95M |
232.79M |
236.05M |
| Adjusted Basic & Diluted Earnings per Share |
|
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.37 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Adjusted Weighted Average Basic & Diluted Shares Outstanding |
|
65.19M |
65.29M |
178.26M |
178.32M |
205.27M |
0.00 |
230.90M |
231.16M |
231.48M |
237.91M |
| Normalized Net Operating Profit after Tax (NOPAT) |
|
160 |
176 |
173 |
392 |
416 |
392 |
402 |
274 |
272 |
369 |
| Normalized NOPAT Margin |
|
66.52% |
66.45% |
54.04% |
62.78% |
64.31% |
66.80% |
92.00% |
52.85% |
50.81% |
62.41% |
| Pre Tax Income Margin |
|
33.25% |
26.94% |
49.72% |
46.01% |
12.23% |
26.55% |
18.47% |
4.18% |
3.48% |
21.69% |
| Debt Service Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| EBIT to Interest Expense |
|
0.00 |
0.00 |
1.21 |
0.00 |
0.00 |
0.00 |
-1.25 |
0.32 |
0.84 |
1.09 |
| NOPAT to Interest Expense |
|
0.00 |
0.00 |
1.20 |
0.00 |
0.00 |
0.00 |
0.68 |
0.30 |
0.75 |
1.08 |
| EBIT Less CapEx to Interest Expense |
|
0.00 |
0.00 |
1.13 |
0.00 |
0.00 |
0.00 |
-1.69 |
-0.20 |
0.09 |
0.62 |
| NOPAT Less CapEx to Interest Expense |
|
0.00 |
0.00 |
1.13 |
0.00 |
0.00 |
0.00 |
0.24 |
-0.22 |
0.00 |
0.61 |
| Payout Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Dividend Payout Ratio |
|
138.44% |
169.88% |
114.97% |
116.52% |
486.01% |
201.06% |
-232.15% |
-357.14% |
2,016.92% |
221.09% |
| Augmented Payout Ratio |
|
138.44% |
169.88% |
114.97% |
116.70% |
486.01% |
143.20% |
-232.15% |
-357.14% |
2,016.92% |
153.13% |
Quarterly Metrics And Ratios for Sabra Healthcare REIT
This table displays calculated financial ratios and metrics derived from Sabra Healthcare REIT's official financial filings.
| Metric |
|
Q3 2022 |
Q4 2022 |
Q1 2023 |
Q2 2023 |
Q3 2023 |
Q4 2023 |
Q1 2024 |
Q2 2024 |
Q3 2024 |
Q4 2024 |
Q1 2025 |
| Growth Metrics |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Revenue Growth |
|
10.45% |
160.32% |
-4.60% |
3.57% |
18.47% |
-1.17% |
5.71% |
10.59% |
9.46% |
15.26% |
12.50% |
| EBITDA Growth |
|
-98.55% |
696.43% |
-22.79% |
11.05% |
9,518.78% |
-10.11% |
5.97% |
-12.84% |
1.92% |
30.02% |
16.97% |
| EBIT Growth |
|
-611.44% |
153.13% |
-68.80% |
39.14% |
165.87% |
-3.19% |
109.37% |
-24.81% |
7.71% |
108.72% |
48.34% |
| NOPAT Growth |
|
-331.89% |
161.07% |
-78.08% |
24.32% |
172.29% |
76.83% |
182.15% |
-25.06% |
55.27% |
118.88% |
49.30% |
| Net Income Growth |
|
-589.72% |
-248.82% |
-123.37% |
26.08% |
69.84% |
120.20% |
376.74% |
13.15% |
297.26% |
172.18% |
53.52% |
| EPS Growth |
|
-540.00% |
-208.33% |
-122.22% |
28.57% |
68.18% |
121.62% |
375.00% |
11.11% |
285.71% |
150.00% |
54.55% |
| Operating Cash Flow Growth |
|
2.14% |
-30.99% |
8.20% |
-8.15% |
-23.28% |
16.50% |
-22.69% |
13.93% |
17.35% |
1.56% |
52.03% |
| Free Cash Flow Firm Growth |
|
249.39% |
2,393.27% |
225.36% |
471.59% |
33.76% |
64.95% |
-52.45% |
-61.76% |
-91.60% |
-73.03% |
3.18% |
| Invested Capital Growth |
|
-6.23% |
-3.65% |
-6.05% |
-7.49% |
-7.73% |
-6.23% |
-2.65% |
-2.89% |
-0.06% |
-1.11% |
-2.57% |
| Revenue Q/Q Growth |
|
-10.69% |
19.68% |
-4.02% |
0.95% |
2.15% |
-0.16% |
2.67% |
5.61% |
1.11% |
5.13% |
0.21% |
| EBITDA Q/Q Growth |
|
-98.82% |
8,846.22% |
378.02% |
12.57% |
2.14% |
-16.40% |
14.13% |
-7.41% |
19.43% |
6.66% |
-0.02% |
| EBIT Q/Q Growth |
|
-329.14% |
141.77% |
116.48% |
135.18% |
8.48% |
-38.61% |
50.65% |
-15.54% |
55.41% |
18.97% |
-2.88% |
| NOPAT Q/Q Growth |
|
-232.55% |
133.43% |
-9.68% |
210.63% |
-22.93% |
-18.22% |
44.12% |
-17.50% |
59.68% |
15.28% |
-1.69% |
| Net Income Q/Q Growth |
|
-397.91% |
-69.68% |
88.83% |
323.34% |
-171.27% |
213.61% |
53.03% |
-8.68% |
24.25% |
56.76% |
-13.69% |
| EPS Q/Q Growth |
|
-414.29% |
-68.18% |
89.19% |
325.00% |
-177.78% |
214.29% |
37.50% |
-9.09% |
30.00% |
53.85% |
-15.00% |
| Operating Cash Flow Q/Q Growth |
|
41.65% |
-37.69% |
1.04% |
2.99% |
18.32% |
-5.38% |
-32.95% |
51.77% |
21.87% |
-18.11% |
0.37% |
| Free Cash Flow Firm Q/Q Growth |
|
375.65% |
-35.65% |
60.69% |
30.36% |
-0.78% |
-20.64% |
-53.68% |
4.85% |
-78.21% |
154.79% |
77.21% |
| Invested Capital Q/Q Growth |
|
-2.45% |
-1.64% |
-3.42% |
-0.17% |
-2.71% |
-0.03% |
0.27% |
-0.42% |
0.12% |
-1.08% |
-1.22% |
| Profitability Metrics |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| EBITDA Margin |
|
0.72% |
53.51% |
52.13% |
58.13% |
58.12% |
48.67% |
52.26% |
45.82% |
54.12% |
54.90% |
54.78% |
| EBIT Margin |
|
-43.13% |
15.05% |
9.69% |
22.58% |
23.98% |
14.75% |
19.20% |
15.35% |
23.60% |
26.70% |
25.88% |
| Profit (Net Income) Margin |
|
-43.71% |
-61.96% |
-7.21% |
15.95% |
-11.13% |
12.66% |
18.87% |
16.32% |
20.05% |
29.90% |
25.76% |
| Tax Burden Percent |
|
111.00% |
-2,431.95% |
119.77% |
95.58% |
107.86% |
93.19% |
96.16% |
98.53% |
101.63% |
98.99% |
99.52% |
| Interest Burden Percent |
|
91.29% |
16.93% |
-62.10% |
73.89% |
-43.02% |
92.14% |
102.23% |
107.87% |
83.61% |
113.11% |
100.00% |
| Effective Tax Rate |
|
0.00% |
3.55% |
0.00% |
1.47% |
0.00% |
2.68% |
1.66% |
1.80% |
-0.90% |
0.81% |
1.02% |
| Return on Invested Capital (ROIC) |
|
-2.04% |
0.70% |
0.67% |
2.06% |
1.66% |
1.37% |
1.98% |
1.59% |
2.60% |
2.97% |
3.02% |
| ROIC Less NNEP Spread (ROIC-NNEP) |
|
-2.76% |
-3.19% |
-0.13% |
1.72% |
0.08% |
1.31% |
1.95% |
1.66% |
2.37% |
3.22% |
3.03% |
| Return on Net Nonoperating Assets (RNNOA) |
|
-2.17% |
-2.43% |
-0.10% |
1.34% |
0.06% |
1.10% |
1.65% |
1.42% |
2.04% |
2.80% |
2.69% |
| Return on Equity (ROE) |
|
-4.22% |
-1.73% |
0.57% |
3.40% |
1.72% |
2.46% |
3.63% |
3.01% |
4.64% |
5.78% |
5.70% |
| Cash Return on Invested Capital (CROIC) |
|
6.40% |
4.28% |
6.29% |
7.90% |
8.95% |
8.01% |
4.67% |
4.79% |
2.04% |
3.52% |
5.32% |
| Operating Return on Assets (OROA) |
|
-3.10% |
1.33% |
0.87% |
2.03% |
2.30% |
1.42% |
1.91% |
1.57% |
2.50% |
2.95% |
2.97% |
| Return on Assets (ROA) |
|
-3.14% |
-5.48% |
-0.64% |
1.43% |
-1.07% |
1.22% |
1.88% |
1.67% |
2.13% |
3.30% |
2.95% |
| Return on Common Equity (ROCE) |
|
-4.22% |
-1.73% |
0.57% |
3.40% |
1.72% |
2.46% |
3.63% |
3.01% |
4.64% |
5.78% |
5.70% |
| Return on Equity Simple (ROE_SIMPLE) |
|
-0.53% |
0.00% |
-4.29% |
-4.19% |
-3.08% |
0.00% |
1.79% |
1.89% |
3.54% |
0.00% |
5.21% |
| Net Operating Profit after Tax (NOPAT) |
|
-32 |
11 |
9.52 |
30 |
23 |
19 |
27 |
22 |
35 |
41 |
40 |
| NOPAT Margin |
|
-27.51% |
7.68% |
7.23% |
22.25% |
16.79% |
13.75% |
19.30% |
15.08% |
23.81% |
26.11% |
25.62% |
| Net Nonoperating Expense Percent (NNEP) |
|
0.72% |
3.90% |
0.80% |
0.34% |
1.58% |
0.06% |
0.02% |
-0.08% |
0.23% |
-0.25% |
-0.01% |
| SG&A Expenses to Revenue |
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| Operating Expenses to Revenue |
|
143.32% |
84.83% |
90.46% |
77.09% |
75.78% |
85.52% |
80.90% |
84.76% |
76.50% |
73.38% |
74.23% |
| Earnings before Interest and Taxes (EBIT) |
|
-49 |
21 |
13 |
30 |
33 |
20 |
27 |
23 |
35 |
42 |
40 |
| Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) |
|
0.82 |
73 |
69 |
77 |
79 |
66 |
73 |
67 |
80 |
86 |
86 |
| Valuation Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Price to Book Value (P/BV) |
|
0.79 |
0.78 |
0.78 |
0.83 |
1.03 |
1.07 |
1.19 |
1.27 |
1.59 |
1.47 |
1.54 |
| Price to Tangible Book Value (P/TBV) |
|
0.80 |
0.79 |
0.79 |
0.84 |
1.05 |
1.08 |
1.20 |
1.28 |
1.61 |
1.48 |
1.55 |
| Price to Revenue (P/Rev) |
|
5.83 |
4.58 |
4.55 |
4.74 |
5.52 |
5.60 |
6.04 |
6.28 |
7.65 |
6.81 |
6.84 |
| Price to Earnings (P/E) |
|
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
217.85 |
66.31 |
66.92 |
44.86 |
31.76 |
29.53 |
| Dividend Yield |
|
10.96% |
11.69% |
11.92% |
11.35% |
9.35% |
9.26% |
8.45% |
7.94% |
6.45% |
7.06% |
6.87% |
| Earnings Yield |
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.46% |
1.51% |
1.49% |
2.23% |
3.15% |
3.39% |
| Enterprise Value to Invested Capital (EV/IC) |
|
0.87 |
0.87 |
0.87 |
0.90 |
1.01 |
1.03 |
1.09 |
1.13 |
1.30 |
1.24 |
1.28 |
| Enterprise Value to Revenue (EV/Rev) |
|
11.41 |
9.32 |
9.16 |
9.37 |
9.83 |
10.02 |
10.46 |
10.59 |
11.86 |
10.79 |
10.72 |
| Enterprise Value to EBITDA (EV/EBITDA) |
|
29.36 |
20.74 |
40.99 |
39.63 |
26.39 |
18.46 |
19.46 |
20.94 |
23.85 |
20.83 |
20.47 |
| Enterprise Value to EBIT (EV/EBIT) |
|
0.00 |
143.23 |
0.00 |
0.00 |
0.00 |
56.30 |
53.42 |
59.70 |
66.68 |
50.59 |
46.84 |
| Enterprise Value to NOPAT (EV/NOPAT) |
|
0.00 |
151.93 |
1,866.33 |
727.07 |
107.67 |
63.07 |
53.84 |
60.11 |
65.71 |
50.99 |
46.47 |
| Enterprise Value to Operating Cash Flow (EV/OCF) |
|
14.29 |
15.28 |
14.60 |
15.36 |
18.24 |
17.85 |
19.92 |
20.02 |
21.86 |
20.53 |
19.29 |
| Enterprise Value to Free Cash Flow (EV/FCFF) |
|
13.22 |
19.89 |
13.43 |
10.96 |
10.85 |
12.43 |
22.92 |
23.30 |
63.68 |
34.89 |
23.73 |
| Leverage & Solvency |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Debt to Equity |
|
0.76 |
0.82 |
0.81 |
0.82 |
0.82 |
0.86 |
0.89 |
0.89 |
0.90 |
0.88 |
0.89 |
| Long-Term Debt to Equity |
|
0.72 |
0.76 |
0.78 |
0.79 |
0.81 |
0.83 |
0.84 |
0.84 |
0.84 |
0.84 |
0.86 |
| Financial Leverage |
|
0.79 |
0.76 |
0.75 |
0.78 |
0.79 |
0.84 |
0.85 |
0.85 |
0.86 |
0.87 |
0.89 |
| Leverage Ratio |
|
1.84 |
1.82 |
1.81 |
1.83 |
1.85 |
1.90 |
1.90 |
1.91 |
1.91 |
1.93 |
1.94 |
| Compound Leverage Factor |
|
1.68 |
0.31 |
-1.12 |
1.36 |
-0.79 |
1.75 |
1.95 |
2.06 |
1.60 |
2.18 |
1.94 |
| Debt to Total Capital |
|
43.27% |
45.06% |
44.61% |
45.12% |
45.02% |
46.28% |
47.10% |
46.97% |
47.37% |
46.86% |
46.97% |
| Short-Term Debt to Total Capital |
|
2.45% |
3.54% |
1.48% |
1.87% |
0.63% |
1.81% |
2.79% |
2.50% |
2.93% |
2.07% |
1.62% |
| Long-Term Debt to Total Capital |
|
40.82% |
41.52% |
43.13% |
43.24% |
44.40% |
44.47% |
44.30% |
44.47% |
44.44% |
44.80% |
45.35% |
| Preferred Equity to Total Capital |
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| Noncontrolling Interests to Total Capital |
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| Common Equity to Total Capital |
|
56.73% |
54.94% |
55.39% |
54.88% |
54.98% |
53.72% |
52.90% |
53.03% |
52.63% |
53.14% |
53.03% |
| Debt to EBITDA |
|
14.53 |
10.78 |
20.97 |
19.84 |
11.75 |
8.31 |
8.44 |
8.68 |
8.72 |
7.90 |
7.51 |
| Net Debt to EBITDA |
|
14.35 |
10.55 |
20.63 |
19.58 |
11.55 |
8.15 |
8.22 |
8.53 |
8.47 |
7.68 |
7.42 |
| Long-Term Debt to EBITDA |
|
13.71 |
9.93 |
20.28 |
19.02 |
11.58 |
7.98 |
7.94 |
8.22 |
8.18 |
7.55 |
7.26 |
| Debt to NOPAT |
|
-1,655.85 |
78.95 |
954.75 |
364.07 |
47.92 |
28.38 |
23.35 |
24.91 |
24.01 |
19.34 |
17.06 |
| Net Debt to NOPAT |
|
-1,634.77 |
77.26 |
939.34 |
359.20 |
47.13 |
27.83 |
22.73 |
24.48 |
23.34 |
18.81 |
16.85 |
| Long-Term Debt to NOPAT |
|
-1,562.09 |
72.75 |
923.06 |
348.95 |
47.26 |
27.27 |
21.97 |
23.58 |
22.53 |
18.48 |
16.47 |
| Noncontrolling Interest Sharing Ratio |
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| Liquidity Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Cash Flow Metrics |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Free Cash Flow to Firm (FCFF) |
|
344 |
221 |
356 |
464 |
460 |
365 |
169 |
177 |
39 |
98 |
175 |
| Operating Cash Flow to CapEx |
|
757.74% |
327.08% |
349.48% |
381.08% |
322.56% |
373.85% |
408.16% |
644.89% |
706.12% |
515.16% |
1,031.26% |
| Free Cash Flow to Firm to Interest Expense |
|
12.71 |
7.94 |
12.46 |
16.37 |
16.34 |
13.07 |
5.95 |
6.05 |
1.31 |
3.51 |
6.44 |
| Operating Cash Flow to Interest Expense |
|
4.01 |
2.42 |
2.39 |
2.48 |
2.96 |
2.82 |
1.86 |
2.73 |
3.31 |
2.85 |
2.96 |
| Operating Cash Flow Less CapEx to Interest Expense |
|
3.48 |
1.68 |
1.71 |
1.83 |
2.04 |
2.06 |
1.40 |
2.31 |
2.84 |
2.29 |
2.67 |
| Efficiency Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Asset Turnover |
|
0.07 |
0.09 |
0.09 |
0.09 |
0.10 |
0.10 |
0.10 |
0.10 |
0.11 |
0.11 |
0.11 |
| Fixed Asset Turnover |
|
0.08 |
0.10 |
0.10 |
0.11 |
0.11 |
0.11 |
0.12 |
0.12 |
0.12 |
0.13 |
0.13 |
| Capital & Investment Metrics |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Invested Capital |
|
5,656 |
5,563 |
5,373 |
5,364 |
5,218 |
5,217 |
5,231 |
5,209 |
5,215 |
5,159 |
5,096 |
| Invested Capital Turnover |
|
0.07 |
0.09 |
0.09 |
0.09 |
0.10 |
0.10 |
0.10 |
0.11 |
0.11 |
0.11 |
0.12 |
| Increase / (Decrease) in Invested Capital |
|
-376 |
-211 |
-346 |
-434 |
-437 |
-347 |
-142 |
-155 |
-3.28 |
-58 |
-134 |
| Enterprise Value (EV) |
|
4,944 |
4,824 |
4,685 |
4,833 |
5,279 |
5,364 |
5,680 |
5,903 |
6,761 |
6,375 |
6,521 |
| Market Capitalization |
|
2,529 |
2,371 |
2,327 |
2,445 |
2,968 |
2,997 |
3,282 |
3,499 |
4,360 |
4,024 |
4,156 |
| Book Value per Share |
|
$13.89 |
$13.23 |
$12.87 |
$12.73 |
$12.41 |
$12.12 |
$11.96 |
$11.93 |
$11.72 |
$11.59 |
$11.36 |
| Tangible Book Value per Share |
|
$13.68 |
$13.06 |
$12.70 |
$12.58 |
$12.27 |
$11.99 |
$11.83 |
$11.81 |
$11.59 |
$11.47 |
$11.25 |
| Total Capital |
|
5,656 |
5,563 |
5,373 |
5,364 |
5,218 |
5,217 |
5,231 |
5,209 |
5,215 |
5,159 |
5,096 |
| Total Debt |
|
2,447 |
2,507 |
2,397 |
2,420 |
2,349 |
2,414 |
2,463 |
2,447 |
2,470 |
2,418 |
2,394 |
| Total Long-Term Debt |
|
2,308 |
2,310 |
2,317 |
2,320 |
2,317 |
2,320 |
2,317 |
2,316 |
2,318 |
2,311 |
2,311 |
| Net Debt |
|
2,416 |
2,453 |
2,358 |
2,388 |
2,311 |
2,367 |
2,397 |
2,404 |
2,401 |
2,351 |
2,365 |
| Capital Expenditures (CapEx) |
|
14 |
21 |
20 |
18 |
26 |
21 |
13 |
12 |
14 |
16 |
7.78 |
| Net Nonoperating Expense (NNE) |
|
19 |
95 |
19 |
8.37 |
38 |
1.47 |
0.60 |
-1.82 |
5.58 |
-5.92 |
-0.22 |
| Net Nonoperating Obligations (NNO) |
|
2,447 |
2,507 |
2,397 |
2,420 |
2,349 |
2,414 |
2,463 |
2,447 |
2,470 |
2,418 |
2,394 |
| Total Depreciation and Amortization (D&A) |
|
50 |
53 |
56 |
47 |
46 |
46 |
46 |
45 |
45 |
44 |
45 |
| Earnings Adjustments |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Adjusted Basic Earnings per Share |
|
($0.22) |
($0.37) |
($0.04) |
$0.09 |
($0.07) |
$0.08 |
$0.11 |
$0.10 |
$0.13 |
$0.20 |
$0.17 |
| Adjusted Weighted Average Basic Shares Outstanding |
|
230.98M |
230.95M |
231.16M |
231.20M |
231.22M |
231.20M |
231.45M |
231.62M |
234.29M |
233.50M |
237.89M |
| Adjusted Diluted Earnings per Share |
|
($0.22) |
($0.37) |
($0.04) |
$0.09 |
($0.07) |
$0.08 |
$0.11 |
$0.10 |
$0.13 |
$0.20 |
$0.17 |
| Adjusted Weighted Average Diluted Shares Outstanding |
|
230.98M |
230.95M |
231.16M |
232.24M |
231.22M |
232.79M |
233.37M |
233.75M |
237.04M |
236.05M |
240.30M |
| Adjusted Basic & Diluted Earnings per Share |
|
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Adjusted Weighted Average Basic & Diluted Shares Outstanding |
|
230.98M |
231.16M |
231.20M |
231.22M |
231.22M |
231.48M |
231.50M |
234.26M |
236.59M |
237.91M |
237.94M |
| Normalized Net Operating Profit after Tax (NOPAT) |
|
43 |
64 |
49 |
78 |
57 |
73 |
84 |
91 |
65 |
100 |
99 |
| Normalized NOPAT Margin |
|
37.92% |
46.75% |
36.87% |
58.40% |
41.97% |
54.20% |
60.11% |
61.93% |
44.09% |
63.74% |
63.53% |
| Pre Tax Income Margin |
|
-39.37% |
2.55% |
-6.02% |
16.69% |
-10.32% |
13.59% |
19.63% |
16.56% |
19.73% |
30.21% |
25.88% |
| Debt Service Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| EBIT to Interest Expense |
|
-1.83 |
0.74 |
0.45 |
1.06 |
1.16 |
0.72 |
0.94 |
0.77 |
1.19 |
1.49 |
1.49 |
| NOPAT to Interest Expense |
|
-1.16 |
0.38 |
0.33 |
1.04 |
0.81 |
0.67 |
0.95 |
0.76 |
1.20 |
1.45 |
1.48 |
| EBIT Less CapEx to Interest Expense |
|
-2.35 |
0.00 |
-0.24 |
0.41 |
0.24 |
-0.04 |
0.48 |
0.35 |
0.72 |
0.93 |
1.21 |
| NOPAT Less CapEx to Interest Expense |
|
-1.69 |
-0.36 |
-0.35 |
0.39 |
-0.11 |
-0.09 |
0.49 |
0.33 |
0.73 |
0.90 |
1.19 |
| Payout Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Dividend Payout Ratio |
|
-1,625.33% |
-357.14% |
-217.11% |
-224.88% |
-313.96% |
2,016.92% |
560.72% |
531.00% |
286.65% |
221.09% |
200.39% |
| Augmented Payout Ratio |
|
-1,625.33% |
-357.14% |
-217.11% |
-224.88% |
-313.96% |
2,016.92% |
560.72% |
531.00% |
286.65% |
153.13% |
200.39% |
Key Financial Trends
Sabra Health Care REIT (NASDAQ: SBRA) has exhibited a generally stable financial profile over the past year, with some notable improvements and challenges observed across its quarterly reports.
Positive financial highlights:
- The Q1 2025 net income attributable to common shareholders was $40.3 million, showing a strong profitability compared to prior quarters.
- Operating cash flow remains robust, with $80.3 million generated in Q1 2025, reflecting ongoing effective cash management.
- Depreciation expense, while significant at approximately $43.5 million in Q1 2025, is consistent over the quarters, indicating stable asset base and capital expenditures.
- Sabra continues to pay stable cash dividends of $0.30 per share each quarter from Q1 2023 through Q1 2025, supporting shareholder returns.
- Total assets remain sizeable and stable around $5.2 to $5.5 billion, reflecting a strong asset base.
- Long-term debt levels have remained relatively consistent near $2.3 billion since early 2023, showing controlled leverage.
- The company shows consistent purchase and sales of investment securities, indicating active portfolio management to optimize returns.
- Stable issuance and repayment of debt around $20 million each quarter suggest active but balanced capital structuring.
- Total non-interest income has grown to $183.6 million by Q1 2025, up from $160-165 million in 2023, showing increasing revenue diversity.
- Net cash from operating activities has remained robust quarter-over-quarter, providing steady cash available for reinvestment and dividends.
Neutral financial observations:
- Interest expense on long-term debt remains high, around $27-29 million per quarter, reflecting sizeable debt financing costs.
- Provision for credit losses is minimal and sometimes negative, indicating stable credit exposure and loan performance.
- There is significant volatility quarter-to-quarter in other special charges and impairment charges, affecting total non-interest expense unpredictably.
- The weighted average shares outstanding remain around 230-240 million, showing no major dilution or stock buybacks recently.
- Net interest income continues to be negative due to interest expense outweighing interest income, a typical profile for a REIT with high debt.
Negative financial factors:
- The company recorded a large net loss of $84.9 million in Q4 2022 due to a significant impairment charge of over $21 million and other special charges.
- Impairment charges have fluctuated substantially, with notable charges such as $15.3 million in Q2 2024 and $7.3 million in Q4 2023, indicating potential asset write-down risks.
- Negative net income was reported in several quarters during 2022 and 2023, including Q3 2023 (-$15 million) and Q1 2023 (-$9.5 million), pointing to past profitability struggles.
- Cash flow from financing activities has been consistently negative, driven by dividend payments and repayments of debt exceeding issuances, which could constrain liquidity.
- Declines in cash and cash equivalents between periods (e.g., Q1 2025 cash fell to $22.7 million from $63 million in Q3 2024) suggest tightening liquidity.
Overall analysis: Sabra Health Care REIT has demonstrated solid operating income and cash flow in recent quarters, with stable asset and liability levels. However, the company faces pressure from high interest expenses and variable non-interest expenses, including impairment charges that have adversely affected earnings in the past. Continued dividends reflect confidence in cash generation, but liquidity trends warrant monitoring. Investors should watch for management's handling of debt costs and asset impairments to sustain profitability going forward.
10/25/25 06:32 AM ETAI Generated. May Contain Errors.